Alejandro Galindo Joins MannKind as Chief Commercial Officer

[kite]

www.globenewswire.com/news-release/2020/07/20/2064394/0/en/Alejandro-Galindo-Joins-MannKind-as-Chief-Commercial-Officer.html


Derek HoWESTLAKE VILLAGE, Calif., July 20, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) today announced that effective August 4, 2020, Alejandro Galindo, M.B.A, M.S., will be leading MannKind’s commercial operations as Chief Commercial Officer. Mr. Galindo will report directly to Michael Castagna, Chief Executive Officer and will serve on the company’s executive leadership team.

“We are excited to welcome Alejandro to MannKind during a critical period of growth. He is an exceptional addition to our executive leadership team and will be a tremendous asset to us as we continue to expand our commercial organization,” said Mr. Castagna. “I’m confident that Alejandro’s strong leadership skills and extensive experience in product development, global expansion, diabetes, and distribution strategy will help position us for success in the future.”

Mr. Galindo joins MannKind with an accomplished track-record of over 25 years in the healthcare, energy, and consumer industries. He spent the past six years at Medtronic as Vice President and President of the Advanced Insulin Management Business Unit, where he led a fast-paced, double-digit growth global business within their diabetes division. Prior to Medtronic, Mr. Galindo spent nine years at General Electric (GE) Healthcare in a variety of leadership roles, leading emerging markets, strategic corporate development and global supply chain operations. Prior to joining GE’s Healthcare division, he spent eleven years in various global leadership positions for the company’s energy and appliance sectors, overseeing advanced manufacturing engineering and product development. Mr. Galindo received a B.Sc. in Industrial & Systems Engineering from Monterrey Institute of Technology, Mexico and M.B.A. and M.S. degrees from Indiana University.

"I’m thrilled to join such an innovative company that is committed to transforming the standard of care for insulin-dependent diabetes and orphan lung diseases,” said Mr. Galindo. “I know MannKind has a bright future ahead, and I look forward driving the commercial strategy and expanding access to novel treatment options for patients with unmet medical needs.”

[goyocafe]

Cost of sales/script just went up by $20. 

[itellthefuture777]

Welcome aboard..(sounds like Alejandro..close nuff

www.youtube.com/watch?v=yv-DcNTOMp4

[kc]

So with his Pedegree to Medtronic makes you wonder what is focus might be going forward.

Let the speculation begin!

[agedhippie]

Jul 20, 2020 10:19:42 GMT -5 kc said:

So with his Pedegree to Medtronic makes you wonder what is focus might be going forward.

Let the speculation begin!

All his experience is in device manufacture. Bluhale?

[sayhey24]

I am going to speculate that Medtronic is going to offer a new device/drug combination product which includes the 780G and afrezza. We know that the best results most will get with the 670G is when combined with afrezza.

Even Aaron Kowalski seems to like using afrezza with the 670G.

Was Galindo still working at Medtronic or was he in need of a job? Of course we have Dr. Kendall leaving Pfizer for MNKD but then again he has told us this is the easiest job he has ever had. Maybe Galindo needed an easy job too?

[jay1ajay1a]

He was with Medtronic for this conference on June 23-24 at DeviceTalks West.

west.devicetalks.com/speaker/alejandro-galindo/

[sayhey24]

So why does a guy who has a pretty good job at Medtronic, wake up one day and decide to go to MNKD? If we are to believe the press release, Galindo spent the past six years at Medtronic as Vice President and President of the Advanced Insulin Management Business Unit, where he led a fast-paced, double-digit growth global business within their diabetes division.

Double digit growth does not usually get you fired. I don't know but here is to "Hoping for MNKD" there is more to this. I sure hope a lot more. The last time Medtronic got involved with one of Al's inventions it worked out pretty well for the shareholders of MiniMed and Medtronic too.

[awesomo]

Jul 20, 2020 13:59:45 GMT -5 sayhey24 said:

So why does a guy who has a pretty good job at Medtronic, wake up one day and decide to go to MNKD? If we are to believe the press release, Galindo spent the past six years at Medtronic as Vice President and President of the Advanced Insulin Management Business Unit, where he led a fast-paced, double-digit growth global business within their diabetes division.

Double digit growth does not usually get you fired. I don't know but here is to "Hoping for MNKD" there is more to this. I sure hope a lot more. The last time Medtronic got involved with one of Al's inventions it worked out pretty well for the shareholders of MiniMed and Medtronic too.

We’ve said this about every hire, especially Kendall. Well, first off, it’s a promotion, being a part of the c-suite > VP or president of a business group. He’s probably gotten a bump in compensation, Mike loves to pay his executives fat packages and they don’t seem to held to much of a performance standard.

Show me some progress, then I might actually care about this hire. Until then, we’re still in the “rest” portion of our business strategy.

[nylefty]

This is from last October:

www.medtechdive.com/news/tavr-vet-in-at-medtronic-diabetes-unit-amid-shakeup/565441/

Medtronic Diabetes is handing the reins to 15-year Medtronic veteran Sean Salmon, previously president of the coronary and structural heart business, the company said Monday. Hooman Hakami, who has led the unit for a little more than five years, will continue in an advisory role "on an as needed basis" through February, but is otherwise leaving Medtronic.

In assuming leadership of the company's diabetes unit, the least lucrative of Medtronic's four core groups, Salmon takes on a growing market for automated insulin delivery systems but increasing competition for new users. Last quarter, Medtronic Diabetes had 3.5% overall growth but faced "more competitive pressure than we'd like in the U.S.," CEO Omar Ishrak told investors in August. Sales in the U.S., which account for about half of the unit's business, declined 5.6%, but grew 13.8% in developed international markets and 22.2% in emerging markets.

[Deleted]

Jul 20, 2020 14:26:37 GMT -5 awesomo said:

Jul 20, 2020 13:59:45 GMT -5 sayhey24 said:

So why does a guy who has a pretty good job at Medtronic, wake up one day and decide to go to MNKD? If we are to believe the press release, Galindo spent the past six years at Medtronic as Vice President and President of the Advanced Insulin Management Business Unit, where he led a fast-paced, double-digit growth global business within their diabetes division.

Double digit growth does not usually get you fired. I don't know but here is to "Hoping for MNKD" there is more to this. I sure hope a lot more. The last time Medtronic got involved with one of Al's inventions it worked out pretty well for the shareholders of MiniMed and Medtronic too.

We’ve said this about every hire, especially Kendall. Well, first off, it’s a promotion, being a part of the c-suite > VP or president of a business group. He’s probably gotten a bump in compensation, Mike loves to pay his executives fat packages and they don’t seem to held to much of a performance standard.

Show me some progress, then I might actually care about this hire. Until then, we’re still in the “rest” portion of our business strategy.

I am not so sure he left on his own.  He could have been PUSHED.  You can write whatever you want in a press release.  It'll be interesting to see how he transforms the sales organization.    

[sayhey24]

Maybe "more competitive pressure than we'd like in the U.S" provides an opening to combine afrezza with their automated insulin systems. Maybe Medtronic teams afrezza up with the Guardian and goes after the T2 market too.

Its been so quite for so long I just can't believe Mike has been just hiding in his basement. Its time MNKD makes a major move because we know what they have been doing the last 5 years is not working. Here we sit on the greatest advance in diabetes care in 100 years and Mike has not figured out how to sell it.

IMO, the time has come. Maybe Galindo is Mike's replacement.

[pguererro]

David Kendall steps down to pursue other interests

[buyitonsale]

The job was not so easy, I guess... or greener pastures somewhere else.

Major set back IMO if true.

[awesomo]

Jul 20, 2020 16:28:46 GMT -5 pguererro said:

David Kendall steps down to pursue other interests

Wow.

It's ok everyone, we still have our Chief People Officer...